https://biocc.eeAvaleht | BioCC OÜBioCC tegeleb teadus- ja arendustööga kogu toiduahela ulatuses – alates loomaaretusest ja -söödast kuni kliiniliste katsete ja tervistedendavate toodete väljatöötamiseni. BioCC pakub nii mikrobioloogilisi- kui ka tootearendusteenuseid. Söödalisandite, toiduainete ja toidulisandite loomisel rakendatakse maailmatasemel innovaatilisi biotehnoloogilisi lahendusi.
Name
NORDWISE BioTech OÜ
Registry code
14877534
VAT number
EE102244599
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
30.12.2019 (5)
Financial year
01.01-31.12
Capital
100 000.00 €
Activity
72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| BioCC OÜ 11077336 | 100% - 100 000.00 EUR | - | - | Founder |
| Ene Tammsaar
| - | Board member | - | |
| Meeli Lindsaar
| - | - | - | Board member |
| Jaanus Murakas
| - | - | - | Board member |
| Meelis Ots
| - | - | - | Board member |
| Pärt Peterson
| - | - | - | Board member |
| Tanel-Taavi Bulitko
| - | - | - | Board member |
| Üllas Jaaska
| - | - | - | Chairman of the board |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | 28 640.95 € | 16 420.18 € | 15 209.32 € | 2 |
| 2024 Q3 | 54 340.93 € | 7 816.79 € | 7 460.44 € | 2 |
| 2024 Q2 | 21 030.67 € | 6 939.95 € | 6 110.37 € | 3 |
| 2024 Q1 | 49 761.47 € | 6 138.74 € | 4 757.19 € | 3 |
| 2023 Q4 | 32 621.03 € | 6 703.52 € | 3 270.32 € | 3 |
| 2023 Q3 | 18 492.96 € | 6 535.24 € | 4 098.13 € | 3 |
| 2023 Q2 | 61 360.39 € | 6 697.81 € | 2 769.07 € | 3 |
| 2023 Q1 | 32 626.5 € | 5 503.04 € | 2 526.81 € | 2 |
| 2022 Q4 | 36 405.86 € | 11 676.76 € | 6 298.96 € | 4 |
| 2022 Q3 | 26 355.42 € | 10 563.98 € | 7 522.66 € | 3 |
| 2022 Q2 | 25 111.16 € | 7 711.5 € | 6 640.8 € | 4 |
| 2022 Q1 | 75 695.29 € | 12 854.78 € | 6 594.33 € | 4 |
| 2021 Q4 | 29 981.57 € | 8 705.06 € | 6 192.14 € | 4 |
| 2021 Q3 | 18 426.25 € | 8 514.78 € | 6 718.44 € | 4 |
| 2021 Q2 | 42 343.16 € | 8 418.13 € | 4 788.56 € | 4 |
| 2021 Q1 | 22 298.28 € | 3 591.26 € | 3 695.15 € | 3 |
| 2020 Q4 | 30 973.92 € | 7 181.27 € | 2 179.42 € | 3 |
| 2020 Q3 | 4 844.81 € | 764.98 € | 611.94 € | 2 |
| 2020 Q2 | 3 060.24 € | 609.11 € | - | - |
| 2020 Q1 | - | - | - | - |
